Rivaroxaban or Aspirin for Extended Treatment of Venous Thromboembolism
Open accessThe DOI matches its Crossref record, with a small difference in title or year; 32 of the 32 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Although many patients with venous thromboembolism require extended treatment, it is uncertain whether it is better to use full- or lower-intensity anticoagulation therapy or aspirin. METHODS: In this randomized, double-blind, phase 3 study, we assigned 3396 patients with venous thromboembolism to receive either once-daily rivaroxaban (at doses of 20 mg or 10 mg) or 100 mg of aspirin. All the study patients had completed 6 to 12 months of anticoagulation therapy and were in equipoise regarding the need for continued anticoagulation. Study drugs were administered for up to 12 months. The primary efficacy outcome was symptomatic recurrent fatal or nonfatal venous thromboembolism, and the principal safety outcome was major bleeding. RESULTS: A total of 3365 patients were included in the intention-to-treat analyses (median treatment duration, 351 days). The primary efficacy outcome occurred in 17 of 1107 patients (1.5%) receiving 20 mg of rivaroxaban and in 13 of 1127 patients (1.2%) receiving 10 mg of rivaroxaban, as compared with 50 of 1131 patients (4.4%) receiving aspirin (hazard ratio for 20 mg of rivaroxaban vs. aspirin, 0.34; 95% confidence interval [CI], 0.20 to 0.59; hazard ratio for 10 mg of rivaroxaban vs. aspirin, 0.26; 95% CI, 0.14 to 0.47; P<0.001 for both comparisons). Rates of major bleeding were 0.5% in the group receiving 20 mg of rivaroxaban, 0.4% in the group receiving 10 mg of rivaroxaban, and 0.3% in the aspirin group; the rates of clinically relevant nonmajor bleeding were 2.7%, 2.0%, and 1.8%, respectively. The incidence of adverse events was similar in all three groups. CONCLUSIONS: Among patients with venous thromboembolism in equipoise for continued anticoagulation, the risk of a recurrent event was significantly lower with rivaroxaban at either a treatment dose (20 mg) or a prophylactic dose (10 mg) than with aspirin, without a significant increase in bleeding rates. (Funded by Bayer Pharmaceuticals; EINSTEIN CHOICE ClinicalTrials.gov number, NCT02064439 .).
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“Consequently, several studies have investigated the role of aspirin for the secondary prevention of VTE. 309,314,315”
From American Society of Hematology 2020 guidelines for management of venous thromboembolism: treatment of deep vein thrombosis and pulmonary embolism (2020) · cites this paper as [314]
The cited source says what the claim attributes to it.
In the citing paper
“Two of these agents, rivaroxaban and apixaban, have been studied at a reduced dose: from 20 mg daily to 10 mg daily for rivaroxaban and 5 mg to 2.5 mg twice daily for apixaban. 306,314”
From American Society of Hematology 2020 guidelines for management of venous thromboembolism: treatment of deep vein thrombosis and pulmonary embolism (2020) · cites this paper as [314]
The cited source says what the claim attributes to it.
In the citing paper
“Three DOACs have been studied for secondary prevention of recurrent VTE after completion of the primary treatment phase. 306,310,314”
From American Society of Hematology 2020 guidelines for management of venous thromboembolism: treatment of deep vein thrombosis and pulmonary embolism (2020) · cites this paper as [314]
The cited source says what the claim attributes to it.
In the citing paper
“We identified 2 RCTs 306,314 to inform this recommendation.”
From American Society of Hematology 2020 guidelines for management of venous thromboembolism: treatment of deep vein thrombosis and pulmonary embolism (2020) · cites this paper as [314]
The cited source says what the claim attributes to it.
In the citing paper
“and a single study comparing 2 doses of the direct oral anticoagulant rivaroxaban and aspirin found that anticoagulation was more effective than aspirin without an increase in bleeding rates. 314”
From American Society of Hematology 2020 guidelines for management of venous thromboembolism: treatment of deep vein thrombosis and pulmonary embolism (2020) · cites this paper as [314]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
A New Equation to Estimate Glomerular Filtration Rate
Levey, A. S., Stevens, L. A., Schmid, C. H., Zhang, Y. (., Castro, A. F., Feldman, H. I., Kusek, J. W., Eggers, P., Van Lente, F., Greene, T., et al. (2009) · Annals of Internal Medicine · doi:10.7326/0003-4819-150-9-200905050-00006 · Cited by 25,603
Prediction of Creatinine Clearance from Serum Creatinine
Cockcroft, D. W., & Gault, H. (1976) · Nephron · doi:10.1159/000180580 · Cited by 15,309
Rivaroxaban versus warfarin in nonvalvular atrial fibrillation
Patel, M. R., Mahaffey, K. W., Garg, J., Pan, G., Singer, D. E., Hacke, W., Breithardt, G., Halperin, J. L., Hankey, G. J., Piccini, J. P., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1009638 · Cited by 9,430
Self-citationSCHULMAN, S., & KEARON, C. (2005) · Journal of Thrombosis and Haemostasis · doi:10.1111/j.1538-7836.2005.01204.x · Cited by 5,009
Antithrombotic Therapy for VTE Disease
Kearon, C., Akl, E. A., Ornelas, J., Blaivas, A., Jimenez, D., Bounameaux, H., Huisman, M., King, C. S., Morris, T. A., Sood, N., et al. (2016) · Chest · doi:10.1016/j.chest.2015.11.026 · Cited by 4,830
Self-citationSCHULMAN, S., ANGERÅS, U., BERGQVIST, D., ERIKSSON, B., LASSEN, M. R., & FISHER, W. (2010) · Journal of Thrombosis and Haemostasis · doi:10.1111/j.1538-7836.2009.03678.x · Cited by 3,756
Oral Rivaroxaban for Symptomatic Venous Thromboembolism
(2010) · New England Journal of Medicine · doi:10.1056/nejmoa1007903 · Cited by 3,237
Büller (2012) · doi:10.1056/nejmoa1113572 · Cited by 2,353
Oral Apixaban for the Treatment of Acute Venous Thromboembolism
Agnelli, G., Buller, H. R., Cohen, A., Curto, M., Gallus, A. S., Johnson, M., Masiukiewicz, U., Pak, R., Thompson, J., Raskob, G. E., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1302507 · Cited by 2,324
Self-citationThe Statistical Analysis of Failure Time Data
Klein, J. P. (1982) · Technometrics · doi:10.1080/00401706.1982.10487769 · Cited by 2,215
Research works printed but not linked: 1
- 2012, MMWR Morb Mortal Wkly Rep, 61, 401
Cited by
Konstantinides, S. V., Meyer, G., Becattini, C., Bueno, H., Geersing, G.-J., Harjola, V.-P., Huisman, M. V., Humbert, M., Jennings, C. S., Jiménez, D., et al. (2020) · European Heart Journal · doi:10.1093/eurheartj/ehz405 · Cited by 4,916
Self-citationSteffel, J., Verhamme, P., Potpara, T. S., Albaladejo, P., Antz, M., Desteghe, L., Haeusler, K. G., Oldgren, J., Reinecke, H., Roldan-Schilling, V., et al. (2018) · European Heart Journal · doi:10.1093/eurheartj/ehy136 · Cited by 2,123
Self-citationKonstantinides, S. V., Meyer, G., Becattini, C., Bueno, H., Geersing, G.-J., Harjola, V.-P., Huisman, M. V., Humbert, M., Jennings, C. S., Jiménez, D., et al. (2019) · European Respiratory Journal · doi:10.1183/13993003.01647-2019 · Cited by 1,619
Self-citationOrtel, T. L., Neumann, I., Ageno, W., Beyth, R., Clark, N. P., Cuker, A., Hutten, B. A., Jaff, M. R., Manja, V., Schulman, S., et al. (2020) · Blood Advances · doi:10.1182/bloodadvances.2020001830 · Cited by 1,489
Self-citationSteffel, J., Collins, R., Antz, M., Cornu, P., Desteghe, L., Haeusler, K. G., Oldgren, J., Reinecke, H., Roldan-Schilling, V., Rowell, N., et al. (2021) · EP Europace · doi:10.1093/europace/euab065 · Cited by 1,132
Antithrombotic Therapy for VTE Disease
Stevens, S. M., Woller, S. C., Kreuziger, L. B., Bounameaux, H., Doerschug, K., Geersing, G.-J., Huisman, M. V., Kearon, C., King, C. S., Knighton, A. J., et al. (2021) · Chest · doi:10.1016/j.chest.2021.07.055 · Cited by 1,043
Self-citationKhan, F., Tritschler, T., Kahn, S. R., & Rodger, M. A. (2021) · The Lancet · doi:10.1016/s0140-6736(20)32658-1 · Cited by 753
Kakkos, S. K., Gohel, M., Baekgaard, N., Bauersachs, R., Bellmunt-Montoya, S., Black, S. A., ten Cate-Hoek, A. J., Elalamy, I., Enzmann, F. K., Geroulakos, G., et al. (2021) · European Journal of Vascular and Endovascular Surgery · doi:10.1016/j.ejvs.2020.09.023 · Cited by 743
Self-citationKaur, R., Kaur, M., & Singh, J. (2018) · Cardiovascular Diabetology · doi:10.1186/s12933-018-0763-3 · Cited by 736
Rivaroxaban for Thromboprophylaxis in High-Risk Ambulatory Patients with Cancer
Khorana, A. A., Soff, G. A., Kakkar, A. K., Vadhan-Raj, S., Riess, H., Wun, T., Streiff, M. B., Garcia, D. A., Liebman, H. A., Belani, C. P., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1814630 · Cited by 719
Self-citationWeitz, J. I., Fredenburgh, J. C., & Eikelboom, J. W. (2017) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2017.09.024 · Cited by 582
Self-citationTherapeutic strategies for thrombosis: new targets and approaches
Mackman, N., Bergmeier, W., Stouffer, G. A., & Weitz, J. I. (2020) · Nature Reviews Drug Discovery · doi:10.1038/s41573-020-0061-0 · Cited by 388
Self-citationMazzolai, L., Aboyans, V., Ageno, W., Agnelli, G., Alatri, A., Bauersachs, R., Brekelmans, M. P. A., Büller, H. R., Elias, A., Farge, D., et al. (2018) · European Heart Journal · doi:10.1093/eurheartj/ehx003 · Cited by 402
Self-citationVenous Thromboembolism: Advances in Diagnosis and Treatment
Tritschler, T., Kraaijpoel, N., Le Gal, G., & Wells, P. S. (2018) · JAMA · doi:10.1001/jama.2018.14346 · Cited by 357
Self-citationHuisman, M. V., Barco, S., Cannegieter, S. C., Le Gal, G., Konstantinides, S. V., Reitsma, P. H., Rodger, M., Noordegraaf, A. V., & Klok, F. A. (2018) · Nature Reviews Disease Primers · doi:10.1038/nrdp.2018.28 · Cited by 336
Khan, F., Rahman, A., Carrier, M., Kearon, C., Weitz, J. I., Schulman, S., Couturaud, F., Eichinger, S., Kyrle, P. A., Becattini, C., et al. (2019) · BMJ · doi:10.1136/bmj.l4363 · Cited by 328
Self-citationKumbhani, D. J., Cannon, C. P., Beavers, C. J., Bhatt, D. L., Cuker, A., Gluckman, T. J., Marine, J. E., Mehran, R., Messe, S. R., Patel, N. S., et al. (2021) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2020.09.011 · Cited by 308
Scridon, A. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms232112772 · Cited by 280
Diagnosis and Treatment of Lower Extremity Venous Thromboembolism: A Review
Chopard, R., Albertsen, I. E., & Piazza, G. (2020) · JAMA · doi:10.1001/jama.2020.17272 · Cited by 244
Martin, K. A., Beyer‐Westendorf, J., Davidson, B. L., Huisman, M. V., Sandset, P. M., & Moll, S. (2021) · Journal of Thrombosis and Haemostasis · doi:10.1111/jth.15358 · Cited by 249
Self-citationPulmonary embolism: update on management and controversies
Duffett, L., Castellucci, L. A., & Forgie, M. A. (2020) · BMJ · doi:10.1136/bmj.m2177 · Cited by 232
Messé, S. R., Gronseth, G. S., Kent, D. M., Kizer, J. R., Homma, S., Rosterman, L., Carroll, J. D., Ishida, K., Sangha, N., & Kasner, S. E. (2020) · Neurology · doi:10.1212/wnl.0000000000009443 · Cited by 205
The dual role of platelet‐innate immune cell interactions in thrombo‐inflammation
Rayes, J., Bourne, J. H., Brill, A., & Watson, S. P. (2020) · Research and Practice in Thrombosis and Haemostasis · doi:10.1002/rth2.12266 · Cited by 185
Direct oral anticoagulants: evidence and unresolved issues
Chan, N., Sobieraj-Teague, M., & Eikelboom, J. W. (2020) · The Lancet · doi:10.1016/s0140-6736(20)32439-9 · Cited by 189
Deep vein thrombosis: update on diagnosis and management
Kruger, P. C., Eikelboom, J. W., Douketis, J. D., & Hankey, G. J. (2019) · Medical Journal of Australia · doi:10.5694/mja2.50201 · Cited by 188
Direct Oral Anticoagulants vs Vitamin K Antagonists in Patients With Antiphospholipid Syndromes
Khairani, C. D., Bejjani, A., Piazza, G., Jimenez, D., Monreal, M., Chatterjee, S., Pengo, V., Woller, S. C., Cortes-Hernandez, J., Connors, J. M., et al. (2023) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2022.10.008 · Cited by 172
Aspirin or Low-Molecular-Weight Heparin for Thromboprophylaxis after a Fracture
Major Extremity Trauma Research Consortium (METRC) (2023) · New England Journal of Medicine · doi:10.1056/nejmoa2205973 · Cited by 169
Kahn, S. R., & de Wit, K. (2022) · New England Journal of Medicine · doi:10.1056/nejmcp2116489 · Cited by 159
Khan, F. A., Tritschler, T., Kimpton, M., Wells, P. S., Kearon, C., Weitz, J. I., Buller, H. R., Raskob, G. E., Ageno, W., Couturaud, F., et al. (2021) · Annals of Internal Medicine · doi:10.7326/m21-1094 · Cited by 152
Self-citationTran, H. A., Gibbs, H. H., Merriman, E., Curnow, J. L., Young, L., Bennett, A., Tan, C.-W., Chunilal, S. D., Ward, C., Baker, R. I., et al. (2019) · The Medical Journal of Australia · doi:10.5694/mja2.50004 · Cited by 152
Mazzolai, L., Ageno, W., Alatri, A., Bauersachs, R. M., Becattini, C., Brodmann, M., Emmerich, J., Konstantinides, S., Meyer, G., Middeldorp, S., et al. (2021) · European Journal of Preventive Cardiology · doi:10.1093/eurjpc/zwab088 · Cited by 153
Self-citationBallestri, S., Romagnoli, E., Arioli, D., Coluccio, V., Marrazzo, A., Athanasiou, A., Girolamo, M. D., Cappi, C., Marietta, M., & Capitelli, M. (2022) · Advances in Therapy · doi:10.1007/s12325-022-02333-9 · Cited by 146
Is Acetylsalicylic Acid a Safe and Potentially Useful Choice for Adult Patients with COVID-19 ?
Bianconi, V., Violi, F., Fallarino, F., Pignatelli, P., Sahebkar, A., & Pirro, M. (2020) · Drugs · doi:10.1007/s40265-020-01365-1 · Cited by 125
Prevention, Diagnostics and Treatment of Deep Vein Thrombosis. Russian Experts Consensus
Seliverstov, E. I., Lobastov, K. V., Ilyukhin, Е. А., Apkhanova, T. V., Akhmetzyanov, R. V., Akhtyamov, I. F., Barinov, V., Bakhmetiev, A. S., Belov, M. V., Александрович, Б. С., et al. (2023) · Journal of Venous Disorders · doi:10.17116/flebo202317031152 · Cited by 121
Antithrombotic Agents: New Directions in Antithrombotic Therapy
Chan, N., & Weitz, J. I. (2019) · Circulation Research · doi:10.1161/circresaha.118.313155 · Cited by 132
Self-citationCreager, M. A., Barnes, G. D., Giri, J., Mukherjee, D., Jones, W. S., Burnett, A. E., Carman, T., Casanegra, A. I., Castellucci, L. A., Clark, S. M., et al. (2026) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2025.11.005 · Cited by 143
Gorog, D. A., Gue, Y. X., Chao, T., Fauchier, L., Ferreiro, J. L., Huber, K., Konstantinides, S., Lane, D. A., Marín, F. R., Oldgren, J., et al. (2022) · Thrombosis and Haemostasis · doi:10.1055/s-0042-1750385 · Cited by 120
Long-term treatment of venous thromboembolism
Kearon, C., & Kahn, S. R. (2020) · Blood · doi:10.1182/blood.2019002364 · Cited by 111
Couturaud, F., Schmidt, J., Sanchez, O., Ballerie, A., Sevestre, M., Meneveau, N. F., Bertoletti, L., Connault, J., Benhamou, Y., Constans, J., et al. (2025) · The Lancet · doi:10.1016/s0140-6736(24)02842-3 · Cited by 118
Risk of recurrent venous thromboembolism according to baseline risk factor profiles
Prins, M. H., Lensing, A. W. A., Prandoni, P., Wells, P. S., Verhamme, P. B., Beyer‐Westendorf, J., Bauersachs, R. M., Bounameaux, H., Brighton, T., Cohen, A. T., et al. (2018) · Blood Advances · doi:10.1182/bloodadvances.2018017160 · Cited by 99
Self-citationAcute pulmonary embolism: a concise review of diagnosis and management
Rayner, M., Darvall, J. N., & Hammerschlag, G. (2018) · Internal Medicine Journal · doi:10.1111/imj.14145 · Cited by 109
Gu, Z., Wei, A., Zhang, C., Wang, X., Zhang, L., Shen, L., Li, Z., Pan, M.-M., Liu, X.-Y., Pu, J., et al. (2019) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2019.05.056 · Cited by 111
Creager, M. A., Barnes, G. D., Giri, J., Mukherjee, D., Jones, W. S., Burnett, A. E., Carman, T., Casanegra, A. I., Castellucci, L. A., Clark, S. M., et al. (2026) · Circulation · doi:10.1161/cir.0000000000001415 · Cited by 250
Baugh, C. W., Levine, M. P., Cornutt, D., Wilson, J. W., Kwun, R., Mahan, C. E., Pollack, C. V., Marcolini, E. G., Milling, T. J., Peacock, W. F., et al. (2019) · Annals of Emergency Medicine · doi:10.1016/j.annemergmed.2019.09.001 · Cited by 101
Venous and Arterial Thromboses: Two Sides of the Same Coin?
Lippi, G., & Favaloro, E. J. (2017) · Seminars in Thrombosis and Hemostasis · doi:10.1055/s-0037-1607202 · Cited by 103
Das, D., Shruthi, N. R., Banerjee, A., Jothimani, G., Duttaroy, A. K., & Pathak, S. (2023) · Frontiers in Nutrition · doi:10.3389/fnut.2023.1221438 · Cited by 90
“Compared to aspirin, rivaroxaban reduced the risk of recurrence in patients with venous thromboembolism without significantly increasing the risk of bleeding (189).”
BackgroundVenous thromboembolism: Recent advancement and future perspective
Yamashita, Y., Morimoto, T., & Kimura, T. (2021) · Journal of Cardiology · doi:10.1016/j.jjcc.2021.08.026 · Cited by 104
Gianesini, S., Obi, A. T., Onida, S., Baccellieri, D., Bissacco, D., Борсук, Д. А., Campisi, C., Campisi, C. C., Cavezzi, A., Chi, Y., et al. (2019) · Phlebology The Journal of Venous Disease · doi:10.1177/0268355519870690 · Cited by 99
Vasanthamohan, L., Boonyawat, K., Chai‐Adisaksopha, C., & Crowther, M. A. (2018) · Journal of Thrombosis and Haemostasis · doi:10.1111/jth.14156 · Cited by 91
When Direct Oral Anticoagulants Should Not Be Standard Treatment
Bejjani, A., Khairani, C. D., Assi, A. A., Piazza, G., Sadeghipour, P., Talasaz, A. H., Fanikos, J. R., Connors, J. M., Siegal, D. M., Barnes, G. D., et al. (2024) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2023.10.038 · Cited by 97
Self-citationUpdate on the management of venous thromboembolism
Bartholomew, J. R. (2017) · Cleveland Clinic Journal of Medicine · doi:10.3949/ccjm.84.s3.04 · Cited by 85
Platelet in thrombo-inflammation: Unraveling new therapeutic targets
Sharma, S. H., Tyagi, T., & Antoniak, S. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.1039843 · Cited by 94
Dawwas, G. K., Brown, J., Dietrich, E., & Park, H. (2019) · The Lancet Haematology · doi:10.1016/s2352-3026(18)30191-1 · Cited by 84
External validation of the DASH prediction rule: a retrospective cohort study
Tosetto, A., Testa, S., Martinelli, I., Poli, D., Cosmi, B., Lodigiani, C., Ageno, W., Stefano, V. D., Falanga, A., Nichele, I., et al. (2017) · Journal of Thrombosis and Haemostasis · doi:10.1111/jth.13781 · Cited by 86
de Winter, M. A., Buller, H. R., Carrier, M., Cohen, A. T., Hansen, J., Kaasjager, K. A. H., Kakkar, A. K., Middeldorp, S., Raskob, G. E., Sørensen, H. T., et al. (2022) · European Heart Journal · doi:10.1093/eurheartj/ehac776 · Cited by 87
Self-citationMonagle, P., Lensing, A. W. A., Thelen, K., Martinelli, I., Male, C., Santamaría, A., Samochatova, E. V., Kumar, R., Holzhauer, S., Saracco, P., et al. (2019) · The Lancet Haematology · doi:10.1016/s2352-3026(19)30161-9 · Cited by 83
Self-citationLong-term mortality after massive, submassive, and low-risk pulmonary embolism
Gupta, R., Ammari, Z. A., Dasa, O., Ruzieh, M., Burlen, J., Shunnar, K. M., Nguyen, H. T., Xie, Y., Brewster, P. S., Chen, T., et al. (2019) · Vascular Medicine · doi:10.1177/1358863x19886374 · Cited by 72
Becatti, M., Emmi, G., Bettiol, A., Silvestri, E., Scala, G. D., Taddei, N., Prisco, D., & Fiorillo, C. (2018) · Clinical & Experimental Immunology · doi:10.1111/cei.13243 · Cited by 71
Gorog, D. A., Gue, Y. X., Chao, T., Fauchier, L., Ferreiro, J. L., Huber, K., Konstantinides, S., Lane, D. A., Marín, F. R., Oldgren, J., et al. (2022) · EP Europace · doi:10.1093/europace/euac020 · Cited by 74
Swan, D., Rocci, A., Bradbury, C. A., & Thachil, J. V. (2018) · British Journal of Haematology · doi:10.1111/bjh.15684 · Cited by 68
Risk of venous thromboembolism in rheumatoid arthritis
Ketfi, C., Boutigny, A., Mohamedi, N., Bouajil, S., Magnan, B., Amah, G., & Dillinger, J. (2020) · Joint Bone Spine · doi:10.1016/j.jbspin.2020.105122 · Cited by 65
COVID-19 and Its Implications for Thrombosis and Anticoagulation
Berkman, S. A., & Tapson, V. F. (2021) · Seminars in Respiratory and Critical Care Medicine · doi:10.1055/s-0041-1722992 · Cited by 65
Moik, F., Colling, M. E., Mahé, I., Jara‐Palomares, L., Pabinger, I., & Ay, C. (2021) · Journal of Thrombosis and Haemostasis · doi:10.1111/jth.15599 · Cited by 63
Plasma contact factors as therapeutic targets
Tillman, B. F., Gruber, A., McCarty, O. J. T., & Gailani, D. (2018) · Blood Reviews · doi:10.1016/j.blre.2018.04.001 · Cited by 65
Extended treatment of venous thromboembolism: a systematic review and network meta-analysis
Wang, K.-L., van Es, N., Cameron, C. G., Castellucci, L. A., Buller, H. R., & Carrier, M. (2018) · Heart · doi:10.1136/heartjnl-2018-313617 · Cited by 61
Rivaroxaban Prophylaxis in Noncirrhotic Portal Vein Thrombosis
Plessier, A., Goria, O., Cervoni, J. P., Ollivier‐Hourmand, I., Bureau, C., Poujol‐Robert, A., Minello, A., Houssel‐Debry, P., Rautou, P., Payancé, A., et al. (2022) · NEJM Evidence · doi:10.1056/evidoa2200104 · Cited by 63
Immunothrombosis and the Role of Platelets in Venous Thromboembolic Diseases
Heestermans, M., Poénou, G., Duchez, A., Hamzeh‐Cognasse, H., Bertoletti, L., & Cognasse, F. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms232113176 · Cited by 61
Áinle, F. N., & Kevane, B. (2020) · Blood Advances · doi:10.1182/bloodadvances.2020002268 · Cited by 60
Treatment Algorithm in Cancer-Associated Thrombosis: Updated Canadian Expert Consensus
Carrier, M., Blais, N., Crowther, M. A., Kavan, P., Gal, G. L., Moodley, O., Shivakumar, S., Suryanarayan, D., Tagalakis, V., Wu, C. M., et al. (2021) · Current Oncology · doi:10.3390/curroncol28060453 · Cited by 62
Antithrombotic Management of Venous Thromboembolism
Renner, E., & Barnes, G. D. (2020) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2020.07.070 · Cited by 59
How I treat heavy menstrual bleeding associated with anticoagulants
Boonyawat, K., O’Brien, S. H., & Bates, S. M. (2017) · Blood · doi:10.1182/blood-2017-07-797423 · Cited by 62
Cerebral Venous Thrombosis: We Should Ask the Right Questions to Get Better Answers
Field, T. S., & Hill, M. D. (2019) · Stroke · doi:10.1161/strokeaha.119.025334 · Cited by 55
Apixaban for Extended Treatment of Provoked Venous Thromboembolism
Piazza, G., Bikdeli, B., Pandey, A. K., Krishnathasan, D., Khairani, C. D., Bejjani, A., Morrison, R. H., Hogan, H., Rashedi, S., Pfeferman, M. B., et al. (2025) · New England Journal of Medicine · doi:10.1056/nejmoa2509426 · Cited by 63
Cardioembolic stroke: everything has changed
Spence, J. D. (2018) · Stroke and Vascular Neurology · doi:10.1136/svn-2018-000143 · Cited by 56
Xu, Y., & Siegal, D. M. (2021) · Journal of Thrombosis and Haemostasis · doi:10.1111/jth.15466 · Cited by 62
Weinberg, E. M., Palecki, J., & Reddy, K. R. (2019) · Seminars in Liver Disease · doi:10.1055/s-0039-1679934 · Cited by 54
Khan, F. A., Tritschler, T., Kimpton, M., Wells, P. S., Kearon, C., Weitz, J. I., Buller, H. R., Raskob, G. E., Ageno, W., Couturaud, F., et al. (2021) · Journal of Thrombosis and Haemostasis · doi:10.1111/jth.15491 · Cited by 58
Self-citationEfficacy and Safety Considerations With Dose-Reduced Direct Oral Anticoagulants: A Review
Bikdeli, B., Tajrishi, F. Z., Sadeghipour, P., Talasaz, A. H., Fanikos, J. R., Lippi, G., Siegal, D. M., Eikelboom, J. W., Monréal, M., Jiménez, D., et al. (2022) · JAMA Cardiology · doi:10.1001/jamacardio.2022.1292 · Cited by 61
Self-citationLindquist, D. E., Stewart, D. W., Brewster, A., Waldroup, C., Odle, B. L., Burchette, J. E., & El‐Bazouni, H. (2018) · Clinical and Applied Thrombosis/Hemostasis · doi:10.1177/1076029618772337 · Cited by 52
Palareti, G., Antonucci, E., Mastroiacovo, D., Ageno, W., Pengo, V., Poli, D., Testa, S., Tosetto, A., & Prandoni, P. (2018) · Journal of Thrombosis and Haemostasis · doi:10.1111/jth.14253 · Cited by 49
Self-citationWu, T., Lv, C., Wu, L., Chen, W., Lv, M., Jiang, S., & Zhang, J. (2021) · Journal of Neurology · doi:10.1007/s00415-021-10448-2 · Cited by 53
Incidence of Venous Thromboembolism in a Racially Diverse Population of Oklahoma County, Oklahoma
Wendelboe, A. M., Campbell, J. E., Ding, K., Bratzler, D. W., Beckman, M. G., Reyes, N., & Raskob, G. E. (2021) · Thrombosis and Haemostasis · doi:10.1055/s-0040-1722189 · Cited by 50
Review Article: Gastrointestinal Bleeding Risk with Direct Oral Anticoagulants
Benamouzig, R., Guenoun, M., Deutsch, D., & Fauchier, L. (2021) · Cardiovascular Drugs and Therapy · doi:10.1007/s10557-021-07211-0 · Cited by 57
Kempny, A., McCabe, C., Dimopoulos, K., Price, L., Wilde, M., Limbrey, R., Gatzoulis, M. Α., & Wort, S. J. (2018) · International Journal of Cardiology · doi:10.1016/j.ijcard.2018.10.001 · Cited by 47
Larsen, T., Garresori, H., Brekke, J., Enden, T. R., Frøen, H., Jacobsen, E. M., Quist‐Paulsen, P., Porojnicu, A. C., Ree, A. H., Torfoss, D., et al. (2022) · Journal of Thrombosis and Haemostasis · doi:10.1111/jth.15666 · Cited by 45
Direct oral anticoagulants after bariatric surgery—What is the evidence?
Leong, R., Chu, D. K., Crowther, M. A., & Mithoowani, S. (2022) · Journal of Thrombosis and Haemostasis · doi:10.1111/jth.15823 · Cited by 45
How I diagnose and treat venous thromboembolism in sickle cell disease
Shet, A. S., & Wun, T. (2018) · Blood · doi:10.1182/blood-2018-03-822593 · Cited by 49
Houghton, D. E., Vlazny, D. T., Casanegra, A. I., Brunton, N. E., Froehling, D. A., Meverden, R. A., Hodge, D. O., Peterson, L. G., McBane, R. D., & Wysokiński, W. E. (2021) · Mayo Clinic Proceedings · doi:10.1016/j.mayocp.2021.04.026 · Cited by 46
Does aspirin prevent venous thromboembolism?
Diep, R. T., & Garcia, D. A. (2020) · Hematology · doi:10.1182/hematology.2020000150 · Cited by 49
Arrington‐Sanders, R., Connell, N. T., Coon, D., Dowshen, N., Goldman, A. L., Goldstein, Z. G., Grimstad, F. W., Javier, N. M., Kim, E., Murphy, M. C., et al. (2022) · Endocrine Practice · doi:10.1016/j.eprac.2022.12.008 · Cited by 44
Vlieg, M. A. M. V. H., Nasserinejad, K., Visser, C., Bramer, W. M., Ashrani, A. A., Bosson, J., Crusan, D. J., D’Alessio, A., Fluharty, M., Ģībietis, V., et al. (2023) · EClinicalMedicine · doi:10.1016/j.eclinm.2023.102194 · Cited by 44
Hypercoagulable states in arterial and venous thrombosis: When, how, and who to test?
Carroll, B., & Piazza, G. (2018) · Vascular Medicine · doi:10.1177/1358863x18755927 · Cited by 48
Sex matters: Practice 5P's when treating young women with venous thromboembolism
Bistervels, I. M., Scheres, L. J. J., Hamulyák, E. N., & Middeldorp, S. (2019) · Journal of Thrombosis and Haemostasis · doi:10.1111/jth.14549 · Cited by 48
Apixaban and rivaroxaban in patients with acute venous thromboembolism
Bott-Kitslaar, D. M., McBane, R. D., Casanegra, A. I., Houghton, D. E., Froehling, D. A., Vlazny, D. T., Ashrani, A. A., Hodge, D. O., Vargas, E. R., Bartlett, M. A., et al. (2019) · Mayo Clinic Proceedings · doi:10.1016/j.mayocp.2018.09.022 · Cited by 43
Changes in the landscape of anticoagulation: a focus on direct oral anticoagulants
Ageno, W., Caramelli, B., Donadini, M. P., Girardi, L., & Riva, N. (2024) · The Lancet Haematology · doi:10.1016/s2352-3026(24)00281-3 · Cited by 55
Current challenges and future prospects in oral anticoagulant therapy
Czuprynska, J., Patel, J. P., & Arya, R. (2017) · British Journal of Haematology · doi:10.1111/bjh.14714 · Cited by 43
Transgender patients and the role of the coagulation clinician
Connors, J. M., & Middeldorp, S. (2019) · Journal of Thrombosis and Haemostasis · doi:10.1111/jth.14626 · Cited by 42
Capell, W. H., Barnathan, E. S., Piazza, G., Spyropoulos, A. C., Hsia, J. A., Bull, S. A., Lipardi, C., Sugarmann, C., Suh, E., Rao, J. P., et al. (2021) · American Heart Journal · doi:10.1016/j.ahj.2021.02.001 · Cited by 44
Provoked versus unprovoked venous thromboembolism: Findings from GARFIELD‐VTE
Ageno, W., Farjat, A. E., Haas, S. K., Weitz, J. I., Goldhaber, S. Z., Turpie, A. G. G., Goto, S., Angchaisuksiri, P., Nielsen, J. D., Kayani, G., et al. (2021) · Research and Practice in Thrombosis and Haemostasis · doi:10.1002/rth2.12482 · Cited by 48
Self-citationManaging thromboembolic risk in patients with hereditary and acquired thrombophilias
Moran, J. P., & Bauer, K. A. (2020) · Blood · doi:10.1182/blood.2019000917 · Cited by 51
Metadata
- Authors
- Weitz, J. I., Lensing, A. W. A., Prins, M. H., Bauersachs, R., Beyer-Westendorf, J., Bounameaux, H., Brighton, T. A., Cohen, A. T., Davidson, B. L., Decousus, H., Freitas, M. C. S., Holberg, G., Kakkar, A. K., Haskell, L., van Bellen, B., Pap, A. F., Berkowitz, S. D., Verhamme, P., Wells, P. S., & Prandoni, P.
- Affiliations
- University of Ottawa (CA)
- University of Geneva (CH)
- University of Padua (IT)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2017-03-30
- Volume
- 376
- Issue
- 13
- Pages
- 1211-1222
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2595086780
- Cited by
- 787
- References
- 32
- Citations by year
- 2026: 58 · 2025: 77 · 2024: 65 · 2023: 49 · 2022: 78 · 2021: 97 · 2020: 92 · 2019: 96 · 2018: 123 · 2017: 50
- FWCI
- 104.37
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Research Portal (King's College London) (publishedVersion, other-oa)
- Pure Amsterdam UMC (publishedVersion, other-oa)
- SERVAL (Université de Lausanne) (publishedVersion, other-oa)
- Archive ouverte UNIGE (University of Geneva) (publishedVersion, other-oa)
- IRIS (submittedVersion)
- Data Archiving and Networked Services (DANS) (submittedVersion)
- HAL (submittedVersion)
- Research Publications (Maastricht University) (submittedVersion, other-oa)
- Dipòsit Digital de la Universitat de Barcelona (Universitat de Barcelona) (submittedVersion, public-domain)
- UCL Discovery (University College London) (submittedVersion)
- Lirias (KU Leuven) (submittedVersion)
- Archive ouverte UNIGE (University of Geneva) (submittedVersion, cc-by)
- Funders
- Amgen
- Bristol-Myers Squibb
- Pfizer
- GlaxoSmithKline
- Sanofi
- Ionis Pharmaceuticals
- Janssen Scientific Affairs
- Novo Nordisk
- Novo Nordisk Fonden (NNF12OC1015957)
- LEO Pharma
- Daiichi Sankyo Europe
- Topics
- Health Sciences › Medicine › Internal Medicine › Venous Thromboembolism Diagnosis and Management
- Health Sciences › Medicine › Hematology › Blood Coagulation and Thrombosis Mechanisms
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Atrial Fibrillation Management and Outcomes
- Keywords
- venous thromboembolism, rivaroxaban, aspirin, long-term anticoagulation, recurrent venous thromboembolism, major bleeding, low-dose rivaroxaban, thromboprophylaxis, direct oral anticoagulants, adverse events, dose comparison, post-thrombotic syndrome
- MeSH terms
- Rivaroxaban, Adult, Aged, Aspirin, Double-Blind Method, Drug Administration Schedule, Female, Hemorrhage, Humans, Male, Middle Aged, Platelet Aggregation Inhibitors, Kaplan-Meier Estimate, Venous Thromboembolism, Secondary Prevention, Intention to Treat Analysis, Factor Xa Inhibitors
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.